California-based biopharmaceutical company Peregrine Pharmaceuticals has reported consolidated net loss of $3.33 million, or $0.01 per diluted share for the third quarter of fiscal 2009 compared to consolidated net loss of $6.15 million, or $0.03 per diluted share for the same period of fiscal 2008.

The company’s total revenues for the third quarter of fiscal 2009 increased 308% to $6.83 million, compared to total revenues of $1.67 million for the same period of fiscal 2008.

The consolidated net loss for the nine months declined 24%, from $17,017,000 in the period ended January 31, 2008 to $12,915,000 in the comparable period in 2009. For the nine months ended January 31, 2009, total revenues increased to $10,284,000, up 98% from the first nine months of fiscal 2008.

At January 31, 2009, the company had $10.9 million in cash and cash equivalents.